Evaluation of 451 Danish Boys With Delayed Puberty: Diagnostic Use of a New Puberty Nomogram and Effects of Oral Testosterone Therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Evaluation of 451 Danish Boys With Delayed Puberty : Diagnostic Use of a New Puberty Nomogram and Effects of Oral Testosterone Therapy. / Lawaetz, Jacob Gerner; Hagen, Casper P; Mieritz, Mikkel Grunnet; Jensen, Martin Blomberg; Petersen, Jørgen Holm; Juul, Anders.

I: Journal of Clinical Endocrinology and Metabolism, Bind 100, Nr. 4, 04.2015, s. 1376-1385.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Lawaetz, JG, Hagen, CP, Mieritz, MG, Jensen, MB, Petersen, JH & Juul, A 2015, 'Evaluation of 451 Danish Boys With Delayed Puberty: Diagnostic Use of a New Puberty Nomogram and Effects of Oral Testosterone Therapy', Journal of Clinical Endocrinology and Metabolism, bind 100, nr. 4, s. 1376-1385. https://doi.org/10.1210/jc.2014-3631

APA

Lawaetz, J. G., Hagen, C. P., Mieritz, M. G., Jensen, M. B., Petersen, J. H., & Juul, A. (2015). Evaluation of 451 Danish Boys With Delayed Puberty: Diagnostic Use of a New Puberty Nomogram and Effects of Oral Testosterone Therapy. Journal of Clinical Endocrinology and Metabolism, 100(4), 1376-1385. https://doi.org/10.1210/jc.2014-3631

Vancouver

Lawaetz JG, Hagen CP, Mieritz MG, Jensen MB, Petersen JH, Juul A. Evaluation of 451 Danish Boys With Delayed Puberty: Diagnostic Use of a New Puberty Nomogram and Effects of Oral Testosterone Therapy. Journal of Clinical Endocrinology and Metabolism. 2015 apr.;100(4):1376-1385. https://doi.org/10.1210/jc.2014-3631

Author

Lawaetz, Jacob Gerner ; Hagen, Casper P ; Mieritz, Mikkel Grunnet ; Jensen, Martin Blomberg ; Petersen, Jørgen Holm ; Juul, Anders. / Evaluation of 451 Danish Boys With Delayed Puberty : Diagnostic Use of a New Puberty Nomogram and Effects of Oral Testosterone Therapy. I: Journal of Clinical Endocrinology and Metabolism. 2015 ; Bind 100, Nr. 4. s. 1376-1385.

Bibtex

@article{870e58c5bf2e4f1aaf3206792848f594,
title = "Evaluation of 451 Danish Boys With Delayed Puberty: Diagnostic Use of a New Puberty Nomogram and Effects of Oral Testosterone Therapy",
abstract = "Context: Few data exist on the diagnostic criteria, and on the effects of puberty induction, in boyswith constitutional delay in growth and puberty (CDGP).Objective: To develop puberty nomograms based on Danish boys with normal pubertal development.To evaluate the different diagnostic criteria and the effect of oral testosterone undecanoate(TU) in boys with CDGP.Design: A cross-sectional and longitudinal study of Danish boys with normal pubertal development(COPENHAGEN puberty study). A retrospective observational study of 451 boys evaluated fordelayed puberty between 1990 and 2013.Setting: Tertiary referral center for pediatric endocrinology.Participants: One hundred and sixty-four (36%) boys evaluated for CDGP were excluded due tomissing data, reclassification, or associated comorbidities, yielding 287 (64%) eligible for analysis.Main Outcome Measures: The number of patients with CDGP classified by the puberty nomogram(genital stage 2 SD for age) versus the classical criteria (genital stage 1 at 14 years). The effectof one year of oral TU treatment on pubertal progression, circulating hormones, height, andpredicted adult height (PAH).Results: Seventy-eight (27%) of the 287 boys had delayed pubertal onset according to the classicalcriteria, whereas 173 (60%) of the 287 boys had impaired pubertal progression according to thepuberty nomogram. Ninety-six (56%) of these 173 boys were treated with oral TU for 0.8 years (0.5;1.3) [median (25th; 75th percentiles)], which resulted in beneficial effects on pubertal progression.Height increased from 1.9 SD (2.5; 1.2) to 1.5 SD (2.1; 0.7) (P .001), and PAH increasedfrom 172.3 cm (170.3; 182.8) to 178.1 cm (171.4; 191.7) (P .001) following one year of treatment.Conclusions: The puberty nomogram evaluates both delayed pubertal onset as well as delayedpubertal progression and allows separation of normal versus abnormal pubertal development.Oral TU treatment was followed by pubertal induction and progression and short-term growthwithout compromising final height.",
author = "Lawaetz, {Jacob Gerner} and Hagen, {Casper P} and Mieritz, {Mikkel Grunnet} and Jensen, {Martin Blomberg} and Petersen, {J{\o}rgen Holm} and Anders Juul",
year = "2015",
month = apr,
doi = "10.1210/jc.2014-3631",
language = "English",
volume = "100",
pages = "1376--1385",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Evaluation of 451 Danish Boys With Delayed Puberty

T2 - Diagnostic Use of a New Puberty Nomogram and Effects of Oral Testosterone Therapy

AU - Lawaetz, Jacob Gerner

AU - Hagen, Casper P

AU - Mieritz, Mikkel Grunnet

AU - Jensen, Martin Blomberg

AU - Petersen, Jørgen Holm

AU - Juul, Anders

PY - 2015/4

Y1 - 2015/4

N2 - Context: Few data exist on the diagnostic criteria, and on the effects of puberty induction, in boyswith constitutional delay in growth and puberty (CDGP).Objective: To develop puberty nomograms based on Danish boys with normal pubertal development.To evaluate the different diagnostic criteria and the effect of oral testosterone undecanoate(TU) in boys with CDGP.Design: A cross-sectional and longitudinal study of Danish boys with normal pubertal development(COPENHAGEN puberty study). A retrospective observational study of 451 boys evaluated fordelayed puberty between 1990 and 2013.Setting: Tertiary referral center for pediatric endocrinology.Participants: One hundred and sixty-four (36%) boys evaluated for CDGP were excluded due tomissing data, reclassification, or associated comorbidities, yielding 287 (64%) eligible for analysis.Main Outcome Measures: The number of patients with CDGP classified by the puberty nomogram(genital stage 2 SD for age) versus the classical criteria (genital stage 1 at 14 years). The effectof one year of oral TU treatment on pubertal progression, circulating hormones, height, andpredicted adult height (PAH).Results: Seventy-eight (27%) of the 287 boys had delayed pubertal onset according to the classicalcriteria, whereas 173 (60%) of the 287 boys had impaired pubertal progression according to thepuberty nomogram. Ninety-six (56%) of these 173 boys were treated with oral TU for 0.8 years (0.5;1.3) [median (25th; 75th percentiles)], which resulted in beneficial effects on pubertal progression.Height increased from 1.9 SD (2.5; 1.2) to 1.5 SD (2.1; 0.7) (P .001), and PAH increasedfrom 172.3 cm (170.3; 182.8) to 178.1 cm (171.4; 191.7) (P .001) following one year of treatment.Conclusions: The puberty nomogram evaluates both delayed pubertal onset as well as delayedpubertal progression and allows separation of normal versus abnormal pubertal development.Oral TU treatment was followed by pubertal induction and progression and short-term growthwithout compromising final height.

AB - Context: Few data exist on the diagnostic criteria, and on the effects of puberty induction, in boyswith constitutional delay in growth and puberty (CDGP).Objective: To develop puberty nomograms based on Danish boys with normal pubertal development.To evaluate the different diagnostic criteria and the effect of oral testosterone undecanoate(TU) in boys with CDGP.Design: A cross-sectional and longitudinal study of Danish boys with normal pubertal development(COPENHAGEN puberty study). A retrospective observational study of 451 boys evaluated fordelayed puberty between 1990 and 2013.Setting: Tertiary referral center for pediatric endocrinology.Participants: One hundred and sixty-four (36%) boys evaluated for CDGP were excluded due tomissing data, reclassification, or associated comorbidities, yielding 287 (64%) eligible for analysis.Main Outcome Measures: The number of patients with CDGP classified by the puberty nomogram(genital stage 2 SD for age) versus the classical criteria (genital stage 1 at 14 years). The effectof one year of oral TU treatment on pubertal progression, circulating hormones, height, andpredicted adult height (PAH).Results: Seventy-eight (27%) of the 287 boys had delayed pubertal onset according to the classicalcriteria, whereas 173 (60%) of the 287 boys had impaired pubertal progression according to thepuberty nomogram. Ninety-six (56%) of these 173 boys were treated with oral TU for 0.8 years (0.5;1.3) [median (25th; 75th percentiles)], which resulted in beneficial effects on pubertal progression.Height increased from 1.9 SD (2.5; 1.2) to 1.5 SD (2.1; 0.7) (P .001), and PAH increasedfrom 172.3 cm (170.3; 182.8) to 178.1 cm (171.4; 191.7) (P .001) following one year of treatment.Conclusions: The puberty nomogram evaluates both delayed pubertal onset as well as delayedpubertal progression and allows separation of normal versus abnormal pubertal development.Oral TU treatment was followed by pubertal induction and progression and short-term growthwithout compromising final height.

U2 - 10.1210/jc.2014-3631

DO - 10.1210/jc.2014-3631

M3 - Journal article

VL - 100

SP - 1376

EP - 1385

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -

ID: 140153704